Antibiotic Concentrations Among Critically Ill Patients
NCT ID: NCT01543334
Last Updated: 2025-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
98 participants
OBSERVATIONAL
2012-03-31
2012-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Beta-lactams Therapeutic Drug Monitoring in Critically Ill Patients
NCT05352997
Daptomycin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-venous Hemodiafiltration, a Dose Finding Study
NCT01212432
Beta-lactam Pharmacokinetics in Secondary Care
NCT03033394
Evaluation of the Efficacy and Safety of Suppressive Therapy With DALBAVANCINE in Device Infections
NCT06089044
Immunosuppression and Intensive Care Unit-acquired Multidrug-resistant Bacteria
NCT06652126
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients
Patients with a vein or artery catheter and who are being administered antibiotics. The latter can be of the following: Amoxicillin-clavulanic acid, ampicillin, piperacillin-tazobactam, penicillin G, flucloxacillin, dicloxacillin, cloxacillin, cefazolin, ceftazidime, ceftriaxone, cefepime, meropenem, imipenem, doripenem, ertapenem; Vancomycin, teicoplanin. (see inclusion/exclusion criteria).
Blood sampling
Blood samples will be harvested in one sequence at any time during the week set for the study. In patients receiving multiple antibiotics, multiple samples can be made (without exceeding the study of three antibiotics, ie a maximum of 6 tubes per patient). Two 3-ml tubes of blood will be collected for beta-lactams and glycopeptides (Sample A taken at half the time of the dosing interval and sample B at 30 minutes before the next dose). When patients receive continuous antibiotic treatment, both samples must be made at least 6 hours apart.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sampling
Blood samples will be harvested in one sequence at any time during the week set for the study. In patients receiving multiple antibiotics, multiple samples can be made (without exceeding the study of three antibiotics, ie a maximum of 6 tubes per patient). Two 3-ml tubes of blood will be collected for beta-lactams and glycopeptides (Sample A taken at half the time of the dosing interval and sample B at 30 minutes before the next dose). When patients receive continuous antibiotic treatment, both samples must be made at least 6 hours apart.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Antibiotic treatment is administered with beta-lactams or glycopeptides administered continuously or intermittently (Can be of the following: Amoxicillin-clavulanic acid, ampicillin, piperacillin-tazobactam, penicillin G, flucloxacillin, dicloxacillin, cloxacillin, cefazolin, ceftazidime, ceftriaxone, cefepime, meropenem, imipenem, doripenem, ertapenem; Vancomycin, teicoplanin).
* A vein or artery catheter is established to facilitate blood sampling (arterial catheter is preferred)
Exclusion Criteria
* Impossible to establish venous or arterial catheter
* Consent not given
* Patient is pregnant, parturient or breastfeeding
* The patient is under tutorship or curatorship
* The patient is participating in another study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nīmes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean Yves Lefrant, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire de Nîmes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CH du Pays d'Aix
Aix-en-Provence, , France
CHU d'Amiens - Hôpital Nord
Amiens, , France
CHU d'Angers - Hôtel-Dieu
Angers, , France
CHU de Clermont Ferrand - Hôpital Estaing
Clermont-Ferrand, , France
CHU de Grenoble - Hôpital A Michallon
Grenoble, , France
APHM - Hôpital Nord
Marseille, , France
CHU de Montpellier - Hôpital Saint-Eloi
Montpellier, , France
CHU de Nice - Hôpital St-Roch
Nice, , France
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, , France
APHP - Hôpital Bichat - Claude Bernard
Paris, , France
CHU de Bordeaux - Hôpital Haut-Lévêque
Pessac, , France
CHU de Rennes - Hôpital PontChaillou
Rennes, , France
CHRU de Strasbourg - Hôpital Civil
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J; DALI Study. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014 Apr;58(8):1072-83. doi: 10.1093/cid/ciu027. Epub 2014 Jan 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-A01339-32
Identifier Type: OTHER
Identifier Source: secondary_id
LOCAL/2011/JYL-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.